2918-LB: Treatment Satisfaction and Fear of Hypoglycemia among People with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections: Data from Saudi Arabia

Introduction and Objective: Continuous subcutaneous insulin infusion (CSII) offers more physiological insulin delivery than multiple daily injections (MDI). Evidence on treatment satisfaction and fear of hypoglycemia (FOH) among people with type 1 diabetes (T1D) in Saudi Arabia remains limited. This study compared glycemic outcomes, treatment satisfaction, and FOH between CSII and MDI users. Methods: Adults with T1D using CSII or MDI at three diabetes clinics in Saudi Arabia completed the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and Hypoglycemia Fear Survey-II (HFS-II). Hemoglobin A1c and time-in-range (TIR) were obtained from electronic records. Results: Among 238 participants (137 MDI, 101 CSII), mean age was 31.4±9.6 years and diabetes duration was 17.6±8.6 years. CSII users had lower A1c (7.01±1.01 vs. 8.16±1.37; p<0.001), higher TIR (66.7±17.8% vs. 51.5±16.8%; p<0.001), greater treatment satisfaction (33.1±4.7 vs. 28.0±7.8; p<0.001), and lower FOH scores (29.25±19.27 vs. 37.58±18.95; p=0.001). After adjustment, CSII use remained associated with higher satisfaction and lower perceived glycemic fluctuations. Conclusion: CSII therapy was associated with better glycemic control, higher treatment satisfaction, and lower FOH, supporting wider access to CSII in Saudi Arabia Disclosure S.A. Alamri: None. K.H. Aburisheh: None. Y. Alekrish: None. R.R. Aldrees: None. D.A. Alsagheir: None. M.E. Al-Sofiani: Speaker's Bureau; Ended; Medtronic, Dexcom, Inc. Research Support; Current; Dexcom, Inc. Research Support; Ended; Medtronic. Speaker's Bureau; Ended; Insulet Corporation, Abbott Diabetes, Sanofi.